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Background: Melanoma is the fastest growing tumor of the skin, which disproportionately affects younger
and middle-aged adults. As melanomas are visible, recognizable, and highly curable while in early stages, early
diagnosis is one of the most effective measures to decrease melanoma-related mortality. Skin self-examination
results in earlier detection and removal of the melanoma. Due to the elevated risk of survivors for developing
subsequent melanomas, monthly self-exams are strongly recommended as part of follow-up care. Yet, only a
minority of high-risk individuals practices systematic and regular self-exams. This can be improved through patient
education. However, dermatological education is effective only in about 50% of the cases and little is known about
those who do not respond. In the current literature, psychosocial variables like distress, coping with cancer, as well
as partner and physician support are widely neglected in relation to the practice of skin self-examination, despite
the fact that they have been shown to be essential for other health behaviors and for adherence to medical advice.
Moreover, the current body of knowledge is compromised by the inconsistent conceptualization of SSE. The main
objective of the current project is to examine psychosocial predictors of skin self-examination using on a rigorous
and clinically sound methodology.
Methods/Design: The longitudinal, mixed-method study examines key psychosocial variables related to the
acquisition and to the long-term maintenance of skin self-examination in 200 patients with melanoma. Practice of
self-exam behaviors is assessed at 3 and 12 months after receiving an educational intervention designed based on
best-practice standards. Examined predictors of skin self-exam behaviors include biological sex, perceived self-exam
efficacy, distress, partner and physician support, and coping strategies. Qualitative analyses of semi-structured
interviews will complement and enlighten the quantitative findings.
Discussion: The identification of short and long-term predictors of skin self-examination and an increased
understanding of barriers will allow health care professionals to better address patient difficulties in adhering to this
life-saving health behavior. Furthermore, the findings will enable the development and evaluation of evidence-
based, comprehensive intervention strategies. Ultimately, these findings could impact a wide range of outreach
programs and secondary prevention initiatives for other populations with increased melanoma risk.
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Melanoma – prevalence, survival and risk factors
Cutaneous melanoma, which disproportionately affects
younger and middle-aged adults, is the fastest growing
skin tumor. It is the most common form of cancer in
women aged 25–29 and is second only to breast cancer in
women 30–34 years old. Approximately 60% of all melano-
mas occur before the age of 65 years [1-5]. Compared to
most other cancers, which generally begin to metastasize
when they reach a diameter of approximately 1 cm, mela-
nomas can metastasize when they are only 1 mm in depth,
which translates into a 1000-fold increase in inherent
metastatic potential [6,7]. Hence, the depth of a melanoma
at diagnosis is the strongest individual predictor of survival
as there are no effective therapies once the tumor has
spread [8,9].
Populations with an increased risk for developing mel-
anoma include individuals previously diagnosed with
melanoma, first-degree relatives of melanoma survivors,
patients with non-melanoma skin cancer, and individuals
with many or atypical moles [10-12]. A personal history
of melanoma is associated with a life-long elevated risk for
developing subsequent melanomas [12-14], with up to 11
of 100 melanoma patients developing a second melanoma,
typically within 7 years of the first [15-18].
There is consensus within the clinical and scientific com-
munities that 1) intervention strategies designed to reduce
cutaneous melanoma-related mortality must focus on early
diagnosis of pre-metastatic tumors [11, p. 50]; and that 2)
the highest impact intervention strategies will target
high-risk individuals [10-12,19,20]. Because melanoma is
recognizable and highly curable when detected early, but
increasingly therapy-resistant and lethal as the tumor
progresses, secondary prevention interventions can have a
significant impact on reducing mortality [12,21-24]. Sec-
ondary prevention of melanoma involves early detection via
clinical skin exams or skin self-exams [10,25].
The importance of skin self-examination (SSE)
About 75% of melanomas are detected by patients
themselves or by spouses, friends, or other lay persons
[26-30]. Early detection programs have been proven
successful for the general public and for high-risk popu-
lations. For example, a large-scale melanoma-screening
program involving participant education on SSE signifi-
cantly reduced melanoma-related mortality by decreas-
ing the incidence of melanomas with a thickness greater
than 0.75 mm [31]. Similarly, an Australian randomized
controlled trial (RCT) found that a population screening
program, which included a melanoma awareness cam-
paign, led to a reduction in thickness of melanomas
diagnosed during the campaign [32,33]. A large-scale
population-based case–control study found that SSE was
significantly associated with decreased risk of secondarymelanoma and of advanced disease, and that SSE
reduced melanoma-related mortality by 63% [34]. In this
study patients who conducted rigorous SSE, using mir-
rors to examine one’s back, presented with significantly
thinner melanomas than participants who did not
perform SSE. A subsequent study with 816 melanoma
patients supported the benefits of SSE as early diagnosis
was significantly related with the practice of SSE [27]. A
prospective study including 2,008 patients diagnosed
with stage I - IV melanoma demonstrated that early de-
tection of recurrence results in a significant benefit
regarding overall survival probability [19]. Finally, in a
study with 1,062 melanoma patients (stages I & II) 19%
of patients experienced a melanoma recurrence, which
was most often self-detected and led directly to seeking
early medical advice [35]. Self-detection, not physician
detection, independently predicted survival in this study.
Consequently, guidelines from the National Comprehen-
sive Cancer Network (NCCN), an alliance of 21 of the
world's leading cancer centers, state that upon comple-
tion of the melanoma staging and treatment procedures
all patients with stage IA to stage IV melanomas should
be advised to self-examine their skin monthly [36]. Der-
matological and cancer associations also recommend the
regular practice of SSE and provide education materials
on SSE conduct for the general public [37-39].
In sum, there is evidence that individuals who perform
SSE present for treatment of melanomas at an earlier
disease phase, have 50% less advanced melanoma and
demonstrate significantly lower melanoma-related mor-
tality [10,27,34,35]. Many melanoma survivors do not,
however, practice regular SSE following their initial treat-
ment. Thus, an important challenge is how to achieve
better adherence to this practice [40-42].
Facilitating skin self-examination
Even though cutaneous melanoma are readily visible on
the skin surface and it is well-known that SSEs are
related to better prognosis [32,40,41,43,44], most melan-
oma survivors do not perform systematic skin exams
regularly [27,34,45,46]. These observations have promp-
ted research efforts to determine factors that may influ-
ence whether SSE is performed. Studies have shown, for
instance, that having a personal or family history of skin
cancer [40] is related to SSE. Demographic characteris-
tics associated with SSE in the general population as well
as in melanoma survivors include being female and hav-
ing a higher level of education [27,40,45]. Unlike medical
and demographic factors linked to SSE, which are not
generally amenable to intervention, psychosocial and edu-
cational factors associated with SSE are potential targets of
interventions to improve adherence to SSE instructions.
Psychosocial and educational factors associated with SSE
behaviors in melanoma survivors and other high-risk
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and SSE [40,47,48], higher perceived susceptibility [40,49],
positive attitude towards SSE [40,50], confidence in being
able to perform an efficacious skin self-exam [40,48-50],
and being comfortable with having one’s partner assist in
SSE [51,52]. There is also preliminary evidence that the
level of anxiety and the psychosocial strain resulting from
a melanoma diagnosis affect self-exam practice [53]. Fur-
thermore, being informed about SSE by a health care
professional has been shown to be associated with SSE per-
formance [45,50,54,55], and several intervention studies in
high-risk populations have reported improvement of SSE
after standardized dermatological education [50,56,57].
However, improved SSE was documented for only 37% to
63% of the participants of these studies. Longer term effects
of the dermatological education could not be determined
as the follow-up period only ranged from 3 to 6 months in
these studies. Furthermore, little is known about the pa-
tients who do not respond to dermatological education.
Given that existing interventions to improve SSE have had
limited success, it is important to better understand the
degree to which patients adhere to SSE and to identify po-
tentially modifiable factors that may influence adherence.
Limitations in existing evidence on psychosocial factors
that may influence skin self-examination
Existing research on the association between psycho-
social factors and SSE has been limited by how SSE
has been operationalized, the limited inclusion of psy-
chosocial variables, and the duration of studies. Esti-
mates of SSE vary substantially depending on the way
the information is elicited [25,58,59]. In some studies,
this information has been collected by simply asking
patients if they perform SSE without inquiring about the
surface of skin examined or by inquiring ambiguously
about frequency (e.g., rarely, sometimes, often) ins-
tead of using specific frequency categories (e.g., weekly,
monthly, twice a year). As a result, rates of thorough
SSE amongst melanoma survivors have ranged between
14% and 75% in different studies [30,34,45,46,60,61]. An-
other limitation of previous research is that key psycho-
logical variables, such as psychological distress, coping
and professional/personal support, are widely neglected
in relation to SSE. First, while distress is a very well
known risk factor for non-compliance with medical
advice in general [62-64], only few studies assessing SSE
included a measure of psychological distress [65,66].
Second, while research has shown a higher prevalence of
avoidant coping in skin cancer patients compared to
both other cancer patients and healthy controls [67-72],
only one study has examined the potential link between
coping strategies and SSE in melanoma survivors [66].
Third, social support plays a crucial role in the psycho-
logical adjustment to living with the threat of melanoma[73,74]. Research indicates that social support and cop-
ing are strongly interdependent in melanoma patients
[69,75]. Research has also shown that physician support
is particularly important for melanoma patients, who
indicated "trusting my doctors" and "following the med-
ical advice exactly" as the two most frequent coping
behaviors right after melanoma removal as well as dur-
ing follow-up care [53]. Yet, to date only one study has
examined coping behaviors in relation to SSE and phys-
ician support of SSE hasn’t been studied at all. Further-
more, research has shown that adherence to health
behavior recommendation tends to decrease over longer
time periods [62,76]. However, previous studies documen-
ting adherence to standardized SSE instructions only
involved a 3 to 6-month follow-up assessment [50,56,57].
And lastly, while the combination of quantitative and quali-
tative methods can provide a more complete understanding
of a phenomenon, mixed-method studies investigating the
barriers and facilitators of SSE are lacking.
In sum, early detection of melanoma via SSE is effect-
ive for decreasing melanoma-related mortality. However,
despite being recommended by clinical care guidelines,
the majority of high-risk individuals do not practice SSE
regularly or thoroughly. Rates of SSE can be improved
through patient education, but little is known about those
who do or do not respond optimally to medical advice on
SSE. Acquiring knowledge on the best predictors of SSE
practice will enable researchers and clinicians to design
intervention protocols to target core issues in melanoma
prevention, and, thus, hopefully, reduce mortality rates
from secondary melanoma.
Study objectives
The main objective of this study is to identify short- and
long-term predictors of SSE after providing best-practice
clinical care, which includes medical advice on SSE, and
to better understand challenges and opportunities for
secondary prevention of melanoma in high-risk individ-
uals. Specific objectives include:
(1) To determine the extent of thorough SSE
performance, defined in terms of completeness and
frequency, at 3 months (i.e., Endpoint 1) and at
12 months (i.e., Endpoint 2) after receiving a
standardized dermatological education session on
SSE during melanoma follow-up care.
(2) To identify psychosocial variables, including
distress, coping strategies, and physician and
partner support that are independently associated
with thorough SSE at 3 months and at 12 months
following a standardized dermatological education
session.
(3) To use qualitative methods to understand
psychosocial factors, including physician and
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patients to affectively, cognitively and behaviorally
adjust to the melanoma diagnosis and to the
continuous need for SSE.
Hypotheses
1. The prevalence of thorough SSE will be higher
during the first 3 months than during month 9 to 12
after standardized dermatological education on SSE.
2. Sex will predict SSE in terms of frequency and
completeness. Psychosocial variables, including
partner and physician support, psychological distress
and coping strategies, will significantly predict
additional variance in SSE performance assessed at
3 months and at 12 months after standardized
dermatological education on SSE.
3. Physician and spousal support of SSE will play an
important role for the patient’s psychological
adjustment to the melanoma diagnosis and to the
continuous need for SSE.
Method/Design
Participants and procedures
Ethical approval of the study protocol was granted
by the Institutional Review Board of the Faculty of Medi-
cine, McGill University (reference no. A11-B39-11B). Eli-
gible patients will include English- and French-speaking
adult patients with a confirmed diagnosis of melanoma
who seek services at McGill teaching hospitals. Together,
these hospitals treat over 400 new melanoma patients an-
nually [77,78]. Previous psychosocial studies with cancer
populations at the same hospitals [30,79,80] and at other
sites [81-92] reported participation rates between 57-86%,
with a mean of 76%. Attrition rates range between 4% and
24% in psychosocial studies with an assessment up to 18 -
months after the treatment of patients with melanoma
[56,93] or other cancers [67,82,83,94-97]. Enrollment will
take place over 2 years and continue until 200 participants
have completed the study. A sample of 200 participants
provides sufficient statistical power for the analyses (for
power estimates see section Data analysis). At all time
points the questionnaires will be provided as paper-pencil
versions. Participants will be asked up to 3 times to mail
back questionnaires completed at home. Interviews will be
conducted over the telephone.
During regular clinic visits up to 12 months after their
melanoma diagnosis, i.e., at time 1 (T1), eligible patients
will be advised by the clinical care staff about the oppor-
tunity to participate in the study. In addition, the study
will be advertised through flyers and posters in the
waiting room area, which will allow interested patients
to proactively contact the research team about study
participation. The research assistant will provide studyinformation to interested patients, verify study eligi-
bility and collect written, informed consent. Participants
will be asked to complete baseline questionnaires on
sociodemographic and illness-related information, past
SSE behaviors, and psychological functioning at the
clinic. Alternatively participants can complete the ques-
tionnaires at home and return them to the research team
by mail. The research assistant (RA) will access the par-
ticipants’ medical charts in order to complete the med-
ical information sheet. The second assessment will take
place in conjunction with the delivery of the dermato-
logical education at the clinic 3 to 6 months after
T1, i.e., at time 2 (T2). Participants will complete ques-
tionnaires about distress, coping strategies, physician
support and about SSE knowledge, attitude, and self-
efficacy. In addition, participants who, at the time of
data collection, report having a spouse (i.e., having a
committed intimate relationship), will be asked to an-
swer questions related to their partner’s impact on SSE
practice. Furthermore, these patients will be asked to
take home a survey for their spouse, which mirrors the
partner-related questions that the patient is asked to an-
swer regarding SSE. Also at time 2, all study participants
will receive a 20-minute standardized dermatological ed-
ucation on SSE derived from empirical evidence
[14,29,47,50,65,98-104] and best practice guidelines
[36,38,105-109]. Patients will be encouraged to attend
the education session together with a significant other
(e.g., spouse, other family member, friend) who could
assist them with SSE. During the education session, the
dermatology-trained RA, i.e., the health educator, will
emphasize the usefulness of monthly whole body exams
as an effective measure to detect suspicious skin lesions
as early as possible. The educator will provide detailed
information about how to conduct an effective SSE. This
will include an explanation of the well-established
ABCDE paradigm (lesion Asymmetry; Border irregular-
ity; Color variation; Diameter; Evolution, e.g. change in
size, shape, symptoms, etc.) [110-113] for the detection
and interpretation of pigmented lesions by lay persons
and health care professionals. Furthermore, the educator
will provide handouts, which will assist participants with
regular SSE, including a summarizing brochure on mel-
anoma [114], a bookmark with color printed examples
of lesions [111], a leaflet providing the link to an online
video modeling skin self-examination [115], and a SSE
Journal to record skin spots of concern and body parts
covered during each home SSE [116,117]. At the end of
this 20-minute session, the educator will encourage the
participant to reflect on their SSE intentions. Subse-
quently the participant will be asked to note down in the
SSE journal if, when, where, and assisted by whom the par-
ticipant plans to conduct self-exams. At time 3 (T3), i.e.,
3 months after the dermatological education, participants
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tress, coping strategies, physician and spousal support
as well as SSE knowledge, attitude, and self-efficacy. In
addition, a 10-minute, structured SSE behavior interview
with the RA will be scheduled for T3 to assess practice of
SSE over the last 3 months. At time 4 (T4), 12 months
after the dermatological education, participants will be in-
vited by letter to complete an assessment identical to T3,
i.e., questionnaires and SSE behavior interview. At T4 a
subsample of 30 patients, which will include the first 15
men and the first 15 women who consent to participate,
will be invited to take part in a 50-minute individual,
semi-structured interview based on the McGill Illness
Narrative Interview [118] focusing on the following ques-
tions: 1) how patients deal with the diagnosis and how
they experience the illness; 2) their experience regarding
SSE, including how they deal with the ongoing need for
thorough SSEs and obstacles to SSE; 3) their experience of
physician support of SSE, or lack thereof, and how they
deal with it; and 4) their experience of partner support of
SSE, or lack thereof, and what facilitates or hinders part-
ner support and how they deal with it. Biological sex is
considered explicitly given that previous melanoma re-
search suggests that this is a key variable in relation to
SSE [27,45,119-121]. Participants will be invited to share
and report their thoughts, feelings, and behaviors in each
of the 4 domains, which were selected based on their rele-
vance to the cancer trajectory and their presumed signifi-
cance for SSE practice.
Measures
Descriptive and independent variables: predictors of skin
self-examination
Study measures were selected based on their wide use in
cancer research, on their psychometric properties, and
on their direct relevance to the objectives of the project.
They are used to assess descriptive and independent var-
iables, which are expected to have an effect on SSE be-
haviors during the first 3 months (T1) and 12 months
(T2) after dermatological education.
The Sociodemographic Information Form [67] includes
questions about age, sex, education, having a spouse, socio-
economic status, and cancer diagnosis. With the Medical
Information Sheet [30] the RA gathers data such as time
since diagnosis, melanoma stage and depth, previous diag-
nosis of cancer, melanoma treatment and disease progres-
sion. The Skin Cancer Prevention Scale [122] captures
whether patients performed SSE and have been advised by
health care providers about SSE prior to their current mel-
anoma diagnosis. The Skin Cancer Knowledge Scale, based
on questionnaires by Hay et al. 2006 [65] and Manne et al.
2006 [45], assesses knowledge regarding melanoma risk,
melanoma warning signs and SSE. The SSE Attitude Scale,
an adaptation of Manne’s SSE Benefits and Barriers Scale[45], assesses perceptions of SSE importance, personal gain
through SSE, and barriers to SSE. The SSE Self-Efficacy
Scale, based on Weinstock et al. 2007 [123], captures an
individual’s self-confidence in performing effective skin self-
exams. The Physician SSE Support Scale [124] inquires
about the perceived interest that the treating physician con-
veys regarding the patient’s practice of SSE. The Berlin
Social Support Scale [125] assesses the patient’s perception
of emotional, instrumental and informational illness sup-
port provided by their spouse (patient perception and part-
ner perception). The Skin Cancer Index [126,127] is a self-
report scale focusing on emotional, social and appearance-
related concerns associated with skin cancer. The Patient
Health Questionnaire, PHQ-4, [128] screens for symptoms
of depression and anxiety. The COPE Inventory [129]
inquires about an individual’s use of coping strategies, e.g.,
mental disengagement, behavioral disengagement, focus on
and venting of emotions, use of instrumental social support,
denial, humor, use of emotional social support, planning
and others.
Dependent variables: skin self-examination
Adherence to medical advice on SSE is assessed at 3 months
(T3) and at 12 months (T4) after the standardized educa-
tion session. Based on prior SSE research [30,45,58] and on
recommendations for a monthly, comprehensive skin self-
exam from the Canadian Dermatology Association [130],
the American Academy of Dermatology [108] and the
American Cancer Society [38], a structured SSE-behavior
interview was developed and pilot tested [30]. During this
10-minute interview the RA records SSE behaviors in terms
of SSE completeness and frequency. With the help of a
calendar and the body map, which participants receive dur-
ing the education session in order to document each SSE at
home, SSE is recorded for five specified areas of the body:
1) head and neck; 2) front upper body including arms and
shoulders; 3) front lower body including groin/genital area,
legs, and feet; 4) back upper body including lower back; 5)
back lower body including buttocks and back of legs. SSE
assistance by significant others and the use of melanoma
pictures during the self-exams will be documented. The
first dependent variable, Completeness of SSE, refers to the
examination of the 5 body areas mentioned above. The RA
inquires about each of these 5 parts of the body for each
skin self-exam reported by the patient over the last three
months at T3 and at T4. The interviewer gives one point
for each body area examined, for a possible total of 5 points
reflecting the completeness, in regards to the 5 body areas,
of each SSE conducted. A mean score (on 5) is calculated
across all SSEs. The second dependent variable is Fre-
quency of SSE over a given time period. Over the period of
3 months covered by the assessment at T3 and at T4, ideal
frequency would be 3 SSES, with more than 3 SSEs
reflecting too high a frequency, and less than 3 reflecting
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many times a patient performed a SSE) over 3 months will
be used to determine if the frequency with which an indi-
vidual patient conducted SSEs was too low, ideal or too
high, which will be used for the data analysis.
Data analysis
In all relevant cases, additional analyses, including inter-
action effects and subsample differences, will be examined.
Data analyses related to objective 1 (i.e., determining the
extent of thorough SSE performance defined in terms of
frequency and completeness): Descriptive and inferential
statistics will be employed to gain a differential picture of
patients’ practice of SSE in terms of completeness and
frequency at T3 and T4 for the total sample as well as for
subsamples according to sex, age, having a partner, etc.
Data analyses related to objective 2 (i.e., identifying psy-
chosocial variables independently associated with thorough
SSE): First, hierarchical multiple regressions will be per-
formed with SSE completeness as dependent variable using
T3 data, i.e., 3 months after standardized dermatological
education. The independent variables described above will
be entered block-wise, i.e., 1st block: sex; 2nd: skin cancer
knowledge, attitude toward SEE; 3rd: self-efficacy for
performing SSE; 4th: skin cancer-specific distress measure;
5th: partner support and physician support; 6th: total score
of the coping measure (note that analyses will be repeated
with the individual coping subscales). Second, a multi-
nomial regression will be conducted with the same pre-
dictor variables and SSE frequency (i.e., too low, ideal and
too high frequency) as the dependent variable. The strat-
egies described for T3 will be repeated using the data
collected at T4, i.e., 12 months after the education session.
With the projected sample size of N = 200, a minimal R2 in-
crement of .08 will be detected with .79 power. The power
for detecting a R2 increment of .09 will be .85. The variance
explained by both blocks and individual variables will be
examined. The two dependent variables are treated separ-
ately because they reflect different aspects of SSE practice.
As a second step, they may also be clustered and the
resulting composite measure of SSE behavior will serve as
the dependent variable in regressions similar to the ones
described above. Data analyses related to objective 3
(using qualitative methods for an in-depth understanding
of psychosocial factors related to SSE): Data saturation in
qualitative theme analysis, depending on the level of struc-
ture of the interview, is often achieved with a sample of
10–15 participants who are examined intensively, while lar-
ger samples typically add only minimal new data [131].
Consensual Qualitative Research [131-133] will be applied
to the semi-structured interviews of 15 male and 15 female
patients. This qualitative method is based on principles of
grounded theory [134] and aims at developing a theory
directly grounded in the phenomena under study. As a firststep, the 2 independent sets of interviews will be theme
analyzed to establish preliminary categorizations through
open coding. To guide this, the following preliminary ques-
tions will be used: how do patients cognitively, affectively
and behaviorally adjust to cancer diagnosis and treatment?;
how and why do patients engage in or refrain from per-
forming SSE?; how do they experience practicing SSE (e.g.,
does SSE evoke discomfort, does it trigger tumor fear, does
it lead to a sense of safety and control?); in which ways do
significant others support or undermine SSE practice?;
do patients find it hard to ask significant others for help
with SSE or do patients feel overwhelmed by a others’
motivation to help?; and in which ways are physicians
experienced as helpful or as non-supportive? Axial coding
will then be conducted by which open codes are reviewed
and synthesized. As a final step, selective coding will
be conducted in order to articulate theories derived from
the data and establish the inter-relations between the
constructs that were found. By definition, Consensual
Qualitative Research is conducted independently by two
raters, who then meet to discuss their coding until a con-
sensus is reached. A third independent rater will be avail-
able to address disagreements. All proposals are then edited
by an editor.
Discussion
Given the lack of therapeutic options for melanoma, the
importance of SSE for the early detection of melanoma,
and the limited body of knowledge regarding psycho-
social predictors of SSE, this project is expected to gen-
erate greatly needed information regarding short- and
long-term facilitators and barriers to SSE. By explaining
which psychosocial factors affect acquisition and mainten-
ance of SSE, the findings will help to tailor health services
and prevention strategies as well as guide professional psy-
chosocial support in order to overcome psychological chal-
lenges for sustained SSE practice. The derived knowledge,
including information about effective self-management
strategies, will not only be disseminated via scientific jour-
nals but also amongst health service providers, e.g., within
the North-American Cancer Patient Education Network
(CPEN), which unites health care professionals to promote
models of excellence in patient, family, and community
education across the continuum of care. Moreover, the
findings are expected to also affect high-risk individuals not
previously diagnosed with melanoma by informing second-
ary prevention efforts for populations such as individuals
with non-melanoma skin cancer, with dysplastic nevi or
with a family history of skin cancer. Lastly, this study is set-
ting the basis for the design of a state-of-the-art psycho-
social intervention program tailored to the SSE risk profile
of an individual. The impact of such a psychological com-
plement to standard dermatological education on optimal
SSE practice can then be evaluated in an RCT.
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